NasdaqCM - Nasdaq Real Time Price USD
Catalyst Pharmaceuticals, Inc. (CPRX)
31.43 +0.00 (+0.02%)
As of 1:53:12 PM EDT. Market Open.
Trade CPRX on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for CPRX
- Previous Close
31.42 - Open
31.42 - Bid 31.39 x 600
- Ask 35.82 x 100
- Day's Range
31.40 - 31.44 - 52 Week Range
19.05 - 32.56 - Volume
565,215 - Avg. Volume
2,204,462 - Market Cap (intraday)
3.846B - Beta (5Y Monthly) 0.74
- PE Ratio (TTM)
18.16 - EPS (TTM)
1.73 - Earnings Date (est.) Aug 5, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
31.67
Recent News
View More
Performance Overview
Trailing total returns as of 6/25/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
CPRX
34.64%
S&P 500 (^GSPC)
7.38%
1-Year Return
CPRX
45.89%
S&P 500 (^GSPC)
20.66%
3-Year Return
CPRX
138.97%
S&P 500 (^GSPC)
69.05%
5-Year Return
CPRX
419.42%
S&P 500 (^GSPC)
71.72%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 6/24/2026
Market Cap
3.85B
Enterprise Value
3.09B
Trailing P/E
18.17
Forward P/E
12.94
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.70
Price/Book (mrq)
3.80
Enterprise Value/Revenue
5.18
Enterprise Value/EBITDA
10.12
Financial Highlights
Profitability and Income Statement
Profit Margin
37.08%
Return on Assets (ttm)
16.27%
Return on Equity (ttm)
24.50%
Revenue (ttm)
596.96M
Net Income Avi to Common (ttm)
221.32M
Diluted EPS (ttm)
1.73
Balance Sheet and Cash Flow
Total Cash (mrq)
755.86M
Total Debt/Equity (mrq)
0.26%
Levered Free Cash Flow (ttm)
171.81M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View MoreRaising target price to $35.00
CATALYST PHARMACEUTICALS INC has an Investment Rating of BUY; a target price of $35.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of High.
RatingPrice TargetWhat does Argus have to say about CPRX?
CATALYST PHARMACEUTICALS INC has an Investment Rating of BUY; a target price of $34.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of High.
RatingPrice TargetWhat does Argus have to say about CPRX?
CATALYST PHARMACEUTICALS INC has an Investment Rating of BUY; a target price of $34.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of High.
RatingPrice TargetWhat does Argus have to say about CPRX?
CATALYST PHARMACEUTICALS INC has an Investment Rating of BUY; a target price of $34.000000; an Industry Subrating of High; a Management Subrating of High; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of High.
RatingPrice Target